Allarity Therapeutics Announces Reverse Stock Split of Common Stock

2 years ago

Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24,…

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

2 years ago

Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal terms included €20M upfront payment,…

CancerVax CEO Ryan Davies Speaks with University of Utah Chemistry Professor about the Future of Therapeutic Research

2 years ago

Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX CEO Ryan Davies to discuss…

Ultimovacs ASA: Annual Report 2022

2 years ago

Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that…

Philips convenes the Annual General Meeting of Shareholders 2023

2 years ago

Liz Doherty David Pyott Abhijit Bhattacharya March 24, 2023  Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today…

OKYO Pharma Announces PDMR Dealing

2 years ago

LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the…

UCB Convening Notice to the General Meeting of theShareholders 2023

2 years ago

CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders for the general meeting of…

Celyad Oncology appoints Georges Rawadi as its new CEO

2 years ago

MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused…

AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development

2 years ago

Emmanuel Hanon, PhD, will chair the company’s scientific advisory board. Professor Peter Piot (MD, PhD) and Professor Patrick Soentjens (MD,…

COMPLETION OF DIRECTED ISSUE OF 11,577,957 NEW B SHARES AND 250,000 EXISTING TREASURY B SHARES

2 years ago

Ambu A/S (“Ambu” of the “Company”) has completed its offering of new B shares and existing treasury B shares (together…